Elanco Animal Health (ELAN) Gets a Hold Rating from Raymond James

Raymond James analyst Elliot Wilbur maintained a Hold rating on Elanco Animal Health (ELAN) today. The company’s shares closed last Tuesday at $30.82.

According to TipRanks.com, Wilbur has 0 stars on 0-5 stars ranking scale with an average return of -2.3% and a 45.2% success rate. Wilbur covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Amphastar Pharmaceuticals, and Amneal Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Elanco Animal Health with a $33.80 average price target, implying a 16.4% upside from current levels. In a report issued on December 9, Argus Research also downgraded the stock to Hold.

See today’s analyst top recommended stocks >>

Based on Elanco Animal Health’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $890 million and GAAP net loss of $135 million. In comparison, last year the company earned revenue of $771 million and had a net profit of $10 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Elanco Animal Health, Inc. engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded on May 3, 2018 and is headquartered in Greenfield, IN.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts